The United Kingdom and the United States have concluded a key commercial pact that will keep no duties on UK medicine exports going into the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has pledged to raise spending on medicines through the public health system. This pledge guarantees that duties on these vital exports will remain at zero for a duration of the next three years.
This deal is in response to earlier statements to hike import taxes on branded drug products, with increases floated up to 100%.
"This agreement between the Britain bolsters the international landscape for new treatments and introduces much-needed balance to American-British drug exports," a release said.
Trade Significance
Pharmaceuticals constitute one of the UK's most significant exports to the America, which is clearly the largest destination for major British pharmaceutical firms.
Statistics indicate that in the 12 months to the end of the third quarter, the UK shipped pharmaceutical products worth £11.1bn to the US. This value accounted for nearly one-fifth of British export trade in that span.
"This agreement protects jobs, stimulates capital expenditure and paves the way for the UK to become a international leader for biotech and pharma," a minister stated.
Detailed British Pledges
The agreement includes several key changes from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it considers new medicines to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a aim to double total health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to control costs will be capped at 15%. Last year, repayments topped 20%.
Broader Context
The deal comes amid a long-running dispute between the drug companies and the ministers over medicine costs and regulatory access.
The disagreement were intensified by claims that US customers were paying a premium for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several major pharmaceutical investments in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
A senior figure stated that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had shrunk as a share of its total funding over the last ten years.
